浙江临床医学
浙江臨床醫學
절강림상의학
ZHEJIANG CLINICAL MEDICAL JOURNAL
2014年
1期
8-9,10
,共3页
肝细胞肝癌%复发%三氧化二砷%肝动脉栓塞化疗
肝細胞肝癌%複髮%三氧化二砷%肝動脈栓塞化療
간세포간암%복발%삼양화이신%간동맥전새화료
Hepatocellular carcinoma%Recurrence%Arsenic trioxide%Transcatheter arterial%chemoembolization
目的:评估As2O3和TACE对肝癌根治术后预防复发的临床疗效比较。方法2010年4月至2012年2月收治48例肝癌根治性术后患者作为研究对象,随机分为两组,As2O3组(A组)24例和TACE组(B组)24例,随访1年,比较两组药物毒副作用、肝癌复发率。结果 As2O3组,1年复发率低于TACE组,但差异无统计学意义;As2O3实验组的Ⅰ/Ⅱ级,恶心/呕吐、发热/寒战、疼痛发生率均明显低于TACE对照组(P<0.05);两组均出现轻-中度肝功能异常,但差异无统计学意义。结论在预防肝癌复发方面,三氧化二砷组略优肝动脉栓塞化疗组,患者不良反应小,耐受性好,值得临床推广。
目的:評估As2O3和TACE對肝癌根治術後預防複髮的臨床療效比較。方法2010年4月至2012年2月收治48例肝癌根治性術後患者作為研究對象,隨機分為兩組,As2O3組(A組)24例和TACE組(B組)24例,隨訪1年,比較兩組藥物毒副作用、肝癌複髮率。結果 As2O3組,1年複髮率低于TACE組,但差異無統計學意義;As2O3實驗組的Ⅰ/Ⅱ級,噁心/嘔吐、髮熱/寒戰、疼痛髮生率均明顯低于TACE對照組(P<0.05);兩組均齣現輕-中度肝功能異常,但差異無統計學意義。結論在預防肝癌複髮方麵,三氧化二砷組略優肝動脈栓塞化療組,患者不良反應小,耐受性好,值得臨床推廣。
목적:평고As2O3화TACE대간암근치술후예방복발적림상료효비교。방법2010년4월지2012년2월수치48례간암근치성술후환자작위연구대상,수궤분위량조,As2O3조(A조)24례화TACE조(B조)24례,수방1년,비교량조약물독부작용、간암복발솔。결과 As2O3조,1년복발솔저우TACE조,단차이무통계학의의;As2O3실험조적Ⅰ/Ⅱ급,악심/구토、발열/한전、동통발생솔균명현저우TACE대조조(P<0.05);량조균출현경-중도간공능이상,단차이무통계학의의。결론재예방간암복발방면,삼양화이신조략우간동맥전새화료조,환자불량반응소,내수성호,치득림상추엄。
Objective To evaluate the effect of As2O3 and TACE in the treatment of recurrence of hepatocellular carcinoma after radical resection. Methods A total of 48 patients with hepatocellular carcinoma,who underwent radical resection from April 2010 to February 2012,were randomly divided into two groups:As2O3 treatment group(study group)and TACE treatment group(control group),the drug side effects and liver cancer recurrence rate were compared. Results The 1-year recurrence rate of As2O3 group was lower than the TACE group,but not statistically significant;in As2O3 l group,the incidence ofⅠ/Ⅱfever/chills,nausea/vomiting and pain rate were significantly lower than the TACE group(P<0.05);both groups showed mild-moderate hepatic dysfunction,but not statistically significant. Conclusion The effect of As2O3 in the prevention of liver cancer recurrence after surgery is better than TACE,as it is an ideal method of treatment with well tolerated and no significant liver toxicity. It is worthy of clinical promotion.